Alpha2-receptor agonists as adjuvants for brachial plexus nerve blocks—A systematic review with meta-analyses
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Alpha2-receptor agonists as adjuvants for brachial plexus nerve blocks—A systematic review with meta-analyses. / Andersen, Jakob H.; Karlsen, Anders; Geisler, Anja; Jæger, Pia; Grevstad, Ulrik; Dahl, Jørgen B.; Mathiesen, Ole.
I: Acta Anaesthesiologica Scandinavica, Bind 66, Nr. 2, 2022, s. 186-206.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Alpha2-receptor agonists as adjuvants for brachial plexus nerve blocks—A systematic review with meta-analyses
AU - Andersen, Jakob H.
AU - Karlsen, Anders
AU - Geisler, Anja
AU - Jæger, Pia
AU - Grevstad, Ulrik
AU - Dahl, Jørgen B.
AU - Mathiesen, Ole
N1 - Publisher Copyright: © 2021 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Background: We review the efficacy and safety of dexmedetomidine and clonidine as perineural or systemic adjuvants for brachial plexus blocks (BPB). Methods: We included randomised controlled trials on upper limb surgery with BPBs in adults, comparing dexmedetomidine with clonidine or either drug with placebo. The primary outcome was duration of analgesia. Secondary outcomes included adverse and serious adverse events. The review was conducted using Cochrane standards, trial sequential analyses (TSA) and Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We included 101 trials with 6248 patients. Overall, duration of analgesia was prolonged with both clonidine (176 min [TSA adj. 95% CI: 118, 205, p <.00001; 33 trials]) and dexmedetomidine (292 min [TSA adj. 95% CI: 245 329, p <.00001; 53 trials]), but was longer for dexmedetomidine than clonidine (205 min [TSA adj. 95% CI: 157, 254, p <.00001; 19 trials]). Compared with placebo, dexmedetomidine was associated with bradycardia (RR 4.2 [95% CI 2.2, 8.3]), and both clonidine (RR 4.5 [95% CI 1.1, 18.3]) and dexmedetomidine (RR 3.9 [95% CI 2.0, 7.5]) were associated with hypotension. Serious adverse events were mostly related to block technique. GRADE-rated quality of evidence was low or very low. Conclusion: Alpha2-receptor agonists used as adjuvants for BPBs lead to a prolonged duration of analgesia, with dexmedetomidine as the most efficient. Alpha2-receptor agonists were associated with increased risk of cardiovascular adverse events. The quality of evidence was low to very low.
AB - Background: We review the efficacy and safety of dexmedetomidine and clonidine as perineural or systemic adjuvants for brachial plexus blocks (BPB). Methods: We included randomised controlled trials on upper limb surgery with BPBs in adults, comparing dexmedetomidine with clonidine or either drug with placebo. The primary outcome was duration of analgesia. Secondary outcomes included adverse and serious adverse events. The review was conducted using Cochrane standards, trial sequential analyses (TSA) and Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We included 101 trials with 6248 patients. Overall, duration of analgesia was prolonged with both clonidine (176 min [TSA adj. 95% CI: 118, 205, p <.00001; 33 trials]) and dexmedetomidine (292 min [TSA adj. 95% CI: 245 329, p <.00001; 53 trials]), but was longer for dexmedetomidine than clonidine (205 min [TSA adj. 95% CI: 157, 254, p <.00001; 19 trials]). Compared with placebo, dexmedetomidine was associated with bradycardia (RR 4.2 [95% CI 2.2, 8.3]), and both clonidine (RR 4.5 [95% CI 1.1, 18.3]) and dexmedetomidine (RR 3.9 [95% CI 2.0, 7.5]) were associated with hypotension. Serious adverse events were mostly related to block technique. GRADE-rated quality of evidence was low or very low. Conclusion: Alpha2-receptor agonists used as adjuvants for BPBs lead to a prolonged duration of analgesia, with dexmedetomidine as the most efficient. Alpha2-receptor agonists were associated with increased risk of cardiovascular adverse events. The quality of evidence was low to very low.
KW - adjuvants
KW - alpha-2-receptor agonists
KW - clonidine
KW - dexmedetomidine
KW - nerve block
KW - regional anaesthesia
U2 - 10.1111/aas.14002
DO - 10.1111/aas.14002
M3 - Review
C2 - 34811722
AN - SCOPUS:85121502542
VL - 66
SP - 186
EP - 206
JO - Acta Anaesthesiologica Scandinavica
JF - Acta Anaesthesiologica Scandinavica
SN - 0001-5172
IS - 2
ER -
ID: 290253825